UC San Diego Health’s Yadira Galindo reports that Moores Cancer Center of UC San Diego Health is launching a pilot clinical study to test a personalized vaccine using individual patient’s mutations to boost an anti-tumor immune response.
Investigators at UC San Diego and La Jolla Institute for Allergy and Immunology (LJI), also of San Diego, will test technology they developed that defines the neoantigens (foreign protein fragments recognized by the immune system) in patient’s cancer. Read Ms. Galindo’s article for more details.
Stephen Schoenberger, PhD
Ezra Cohen, MD